Clinical Trial Update: Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update for a neurokinin-1 receptor antagonist addressing itch in epidermolysis bullosa patients; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa
• Pruritus

Drugs mentioned

• neurokinin-1 receptor antagonist

Snippet

Sponsor: Jean Yuh Tang | Conditions: Epidermolysis Bullosa, Pruritus | Phase 2 | Status: COMPLETED | Results posted: 2019-07-02